未来的嵌合抗原受体T细胞
综述指出,CAR T细胞已革新复发/难治CD19阳性白血病和淋巴瘤的治疗,但多数患者无法获得持久缓解;原因与CAR T细胞本身的设计和制备工艺有关,这些因素高度可修改和优化。临床前工作已开始应对这些主要障碍,为更安全、更有效的潜在现货型产品铺路。
要点
- CAR T细胞治疗革新了复发/难治CD19阳性白血病和淋巴瘤的治疗。
- 多数接受治疗的患者无法达到持久缓解。
- 临床前工作已开始应对主要障碍,为更安全、更有效的潜在现货型产品铺路。
核心结论
- CAR T细胞治疗革新了复发/难治CD19阳性白血病和淋巴瘤的治疗,但多数患者无法获得持久缓解;原因与CAR T细胞本身的设计和制备工艺有关,这些因素高度可修改和优化。
- 临床前工作已开始应对这些主要障碍,为更安全、更有效的潜在现货型产品铺路;部分进展将转化至临床,开启未来CAR T细胞时代。
研究设计与样本
- 综述,未报告检索范围。
主要发现
- 多数接受CAR T细胞治疗的患者无法获得持久缓解。
- 临床前工作已开始应对主要障碍,为更安全、更有效的潜在现货型产品铺路。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CAR T cells have revolutionized the treatment of relapsed and refractory CD19-positive leukemia and lymphoma. Unfortunately, the majority of patients treated will not achieve durable remissions. Reasons for these suboptimal clinical outcomes can be tied back to intrinsic CAR T cell design and manufacturing processes, factors that are highly amenable to modification and improvement. As CAR T cell therapy is being deployed in spaces outside of CD19-positive disease, these limitations, complications, and setbacks need to be overcome, allowing for the full potential of this novel therapy to be realized. Preclinical work has begun tackling these major roadblocks, paving the way for potentially off-the-shelf products that are safer and more potent. In time, a number of these advances will be translated to the clinic and usher in an era of CARs of the future.
引用
- Daniyan AF, Brentjens RJ. CARs of the future. Am J Hematol. 2019. PMID: 30680777. doi:10.1002/ajh.25416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。